Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goals of this trial are: 1) To evaluate the safety and tolerability of C3 administration
with Gemcitabine; and 2) To assess the disease response following C3 administration with
Gemcitabine. The main question it aims to answer are: 1) Is C3 in combination with
Gemcitabine safe, tolerable, and effective for reducing improving advanced stage pancreatic
cancer? and 2) Can C3 in combination with Gemcitabine prolong the lives of patients with
advanced stage pancreatic cancer. Participants will receive a combination of metformin (850
mg twice a day), digoxin (0.25 mg once a day), and simvastatin (20 mg once a day), also known
as C3, and Gemcitabine (as per standard of care) for 2 years. If patients decline
Gemcitabine, they will be offered the C3 medications only.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
State University of New York - Downstate Medical Center